Hidden muscle loss may affect ovarian cancer treatment
NCT ID NCT05415527
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study checks for muscle loss (sarcopenia) in 25 women with advanced ovarian cancer before they start chemotherapy. Using CT scans, researchers want to see how common this condition is and if it affects treatment timing. The goal is to better understand how muscle health relates to cancer care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE EPITHELIAL OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Bergonié
Bordeaux, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital therapy aims to tame the fear that haunts cancer survivors
- New PET tracer could spot cancers that standard scans overlook
- Can a mesh shield ovarian cancer patients from painful hernias?
- Two-Drug combo targets Hard-to-Treat ovarian cancer
- New hope for Hard-to-Treat ovarian cancer: drug combo trial launches
- Can Mind-Body techniques and drugs ease stress during ovarian cancer surgery?